Acquisition

Laprophan's $223M Casablanca IPO to fund Polymedic buyout

What's the deal? Moroccan pharmaceutical group LaprophanDealroom has a profile for this one. Try Dealroom → is raising up to 2,220,000,000 MAD (≈$223 million) in an initial public offering on the Casablanca Stock Exchange, priced at 341 MAD per share. The expected market value is about 5,900,000,000 MAD. Part of the proceeds is earmarked for its purchase of the laboratory PolymedicDealroom has a profile for this one. Try Dealroom →.

Why now? In October 2026, Laprophan signed a deal for 100% of Corporate Investment Holding, Polymedic's parent company, pending approval from Morocco's Competition Council. The offer, approved by the capital markets authority (AMMC) on October 28, saw subscriptions run from November 9 to November 17. Trading begins on November 25.

How is it structured? The offer combines a capital increase and a sale of existing shares, representing about 37.6% of capital. It includes 4,105,500 new shares and 2,412,200 existing shares, spread across three tranches — including one for employees and executives priced at 273 MAD.

What's the endgame? Founded in Casablanca in 1949, Laprophan employs about 1,450 people, holds more than 1,300 marketing authorisations and runs four production sites in Morocco and Switzerland, selling in 52 countries. Chief executive Farid Bennis called the laboratory a "national asset." The firm has been expanding through acquisitions, buying AIF Pharma and a stake in Botanic PharmaDealroom has a profile for this one. Try Dealroom → in 2024, and a majority stake in Swiss firm RivopharmDealroom has a profile for this one. Try Dealroom → in 2026.

The numbers: Consolidated revenue rose from 1,503,000,000 MAD in 2023 to 1,820,000,000 MAD in 2025, about 10% a year. Net income reached 109,400,000 MAD in 2025, up 33.9%, equal to 6.0% of revenue versus 4.0% in 2023. First-half 2026 revenue was 1,354,000,000 MAD, up 11.4%.

Who's backing it? Investor consortium Mediterrania Capital PartnersDealroom has a profile for this one. Try Dealroom → entered Laprophan's capital in 2023. CFG Finance is financial adviser and global coordinator, with CFG Marches as lead manager and Attijari Intermediation as co-lead manager.

The signal: Laprophan is using public markets to consolidate Morocco's pharmaceutical sector, folding in a decades-old rival while deepening cross-border reach. The deal turns an acquisition strategy into a listed growth story on the Casablanca exchange.

Read more: radarr.africa

Image credit: Laprophan

More top stories